Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.

Published Date: 13 Nov 2023

A novel imaging agent called 68Ga-ABY-025 has the ability to forecast the early metabolic reaction to treatment that targets the human epidermal growth factor receptor 2 (HER2).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

PET-CT finds further-reaching metastases in patients with locally advanced breast cancer.

2.

Pancreatic cancer RNA vaccine shows durable T cell immunity

3.

Patients value communication skills from cancer surgeons across six key areas, according to research

4.

Why Did Rare Cancer Shrink on Its Own?

5.

Two medications might work better for breast cancers that are resistant to one.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot